Vical CEO Purchases $468,600 in Stock (VICL)
Vical (NASDAQ:VICL) CEO Vijay B. Samant bought 330,000 shares of the company’s stock in a transaction that occurred on Friday, January 10th. The stock was purchased at an average cost of $1.42 per share, with a total value of $468,600.00. Following the completion of the acquisition, the chief executive officer now directly owns 950,726 shares of the company’s stock, valued at approximately $1,350,031. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Vical (NASDAQ:VICL) traded up 7.09% on Tuesday, hitting $1.435. The stock had a trading volume of 2,336,906 shares. Vical has a one year low of $1.01 and a one year high of $4.51. The stock has a 50-day moving average of $1.16 and a 200-day moving average of $1.7. The company’s market cap is $124.5 million.
Vical (NASDAQ:VICL) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.11) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.10) by $0.01. The company had revenue of $1.50 million for the quarter, compared to the consensus estimate of $1.82 million. During the same quarter in the prior year, the company posted ($0.09) earnings per share. The company’s quarterly revenue was down 31.8% on a year-over-year basis. Analysts expect that Vical will post $-0.42 EPS for the current fiscal year.
Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (NASDAQ:VICL) delivery technologies for the prevention and treatment of serious or life-threatening diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.